{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:16:05Z","timestamp":1788984965648,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jiph.2024.05.007","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T11:47:33Z","timestamp":1715687253000},"page":"102450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Risk factors for COVID-19 hospitalisation after booster vaccination during the Omicron period: A French nationwide cohort study"],"prefix":"10.1016","volume":"17","author":[{"given":"Agathe","family":"Turpin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Semenzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Le Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Jo\u00eblle","family":"Jabagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Bouillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Drouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukshe","family":"Kanagaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Weill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Dray-Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-6370","authenticated-orcid":false,"given":"J\u00e9r\u00e9mie","family":"Botton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2024.05.007_bib1","unstructured":"Coronavirus: chiffres cl\u00e9s et \u00e9volution de la COVID-19 en France et dans le Monde [Internet]. [cit\u00e9 8 nov 2022]. Disponible sur: \u3008https:\/\/www.santepubliquefrance.fr\/dossiers\/coronavirus-covid-19\/coronavirus-chiffres-cles-et-evolution-de-la-covid-19-en-france-et-dans-le-monde\u3009."},{"key":"10.1016\/j.jiph.2024.05.007_bib2","unstructured":"Courtejoie N. (DREES\/OSAM\/BAMEDS). Caract\u00e9ristiques socio-\u00e9conomiques des individus aux formes s\u00e9v\u00e8res de Covid-19 au fil des vagues \u00e9pid\u00e9miques; 2022;56."},{"key":"10.1016\/j.jiph.2024.05.007_bib3","article-title":"Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people","volume":"8","author":"Semenzato","year":"2021","journal-title":"Lancet Reg Health Eur"},{"issue":"7821","key":"10.1016\/j.jiph.2024.05.007_bib4","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jiph.2024.05.007_bib5","unstructured":"Avis n\u00b0 2021.0083\/AC\/SESPEV du 24 novembre 2021 du coll\u00e8ge de la Haute Autorit\u00e9 de sant\u00e9 relatif \u00e0 l\u2032int\u00e9gration des personnes de 18 ans et plus dans la campagne de rappel d\u00e8s que 5 mois se sont \u00e9coul\u00e9s depuis la compl\u00e9tude du premier sch\u00e9ma vaccinal [Internet]. Haute Autorit\u00e9 de Sant\u00e9. [cit\u00e9 4 nov 2022]. Disponible sur: \u3008https:\/\/www.has-sante.fr\/jcms\/p_3301353\/fr\/avis-n-2021\u20130083\/ac\/sespev-du-24-novembre-2021-du-college-de-la-haute-autorite-de-sante-relatif-a-l-integration-des-personnes-de-18-ans-et-plus-dans-la-campagne-de-rappel-des-que-5-mois-se-sont-ecoules-depuis-la-completude-du-premier-schema-vaccinal\u3009."},{"key":"10.1016\/j.jiph.2024.05.007_bib6","unstructured":"VaccinTracker Covid19: nombre de fran\u00e7ais vaccin\u00e9s\u2013CovidTracker [Internet]. [cit\u00e9 16 oct 2023]. Disponible sur: \u3008https:\/\/covidtracker.fr\/vaccintracker\/\u3009."},{"key":"10.1016\/j.jiph.2024.05.007_bib7","unstructured":"Avis n\u00b0 2022.0016\/AC\/SESPEV du 17 mars 2022 du coll\u00e8ge de la Haute Autorit\u00e9 de sant\u00e9 relatif \u00e0 la place d\u2032un deuxi\u00e8me rappel des vaccins contre la COVID-19 dans la strat\u00e9gie vaccinale [Internet]. Haute Autorit\u00e9 de Sant\u00e9. [cit\u00e9 17 janv 2023]. Disponible sur: \u3008https:\/\/www.has-sante.fr\/jcms\/p_3325043\/fr\/avis-n-2022\u20130016\/ac\/sespev-du-17-mars-2022-du-college-de-la-haute-autorite-de-sante-relatif-a-la-place-d-un-deuxieme-rappel-des-vaccins-contre-la-covid-19-dans-la-strategie-vaccinale\u3009."},{"key":"10.1016\/j.jiph.2024.05.007_bib8","unstructured":"Avis n\u00b02022.0043\/AC\/SESPEV du 13 juillet 2022 du Coll\u00e8ge de la Haute Autorit\u00e9 de sant\u00e9 relatif \u00e0 la place d\u2032une dose de rappel additionnelle des vaccins contre la Covid-19 dans la strat\u00e9gie vaccinale [Internet]. Haute Autorit\u00e9 de Sant\u00e9. [cit\u00e9 17 janv 2023]. Disponible sur: \u3008https:\/\/www.has-sante.fr\/jcms\/p_3352538\/fr\/avis-n2022\u20130043\/ac\/sespev-du-13-juillet-2022-du-college-de-la-haute-autorite-de-sante-relatif-a-la-place-d-une-dose-de-rappel-additionnelle-des-vaccins-contre-la-covid-19-dans-la-strategie-vaccinale\u3009."},{"key":"10.1016\/j.jiph.2024.05.007_bib9","unstructured":"Coronavirus: chiffres cl\u00e9s et \u00e9volution de la COVID-19 en France et dans le Monde [Internet]. [cit\u00e9 8 nov 2022]. Disponible sur: \u3008https:\/\/www.santepubliquefrance.fr\/dossiers\/coronavirus-covid-19\/coronavirus-chiffres-cles-et-evolution-de-la-covid-19-en-france-et-dans-le-monde\u3009."},{"key":"10.1016\/j.jiph.2024.05.007_bib10","unstructured":"Suarez-Castillo M. (DREES\/OSAM\/LABSANTE). Estimation de l\u2032efficacit\u00e9 vaccinale contre les formes graves de Covid-19.:34."},{"key":"10.1016\/j.jiph.2024.05.007_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2021-000104","article-title":"Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study","volume":"1","author":"Bouillon","year":"2022","journal-title":"bmjmed"},{"issue":"3","key":"10.1016\/j.jiph.2024.05.007_bib12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.vaccine.2021.12.009","article-title":"Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines","volume":"40","author":"Botton","year":"2022","journal-title":"Vaccine"},{"issue":"10309","key":"10.1016\/j.jiph.2024.05.007_bib13","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2024.05.007_bib14","article-title":"Characteristics associated with the residual risk of severe COVID-19 after a complete vaccination schedule: a cohort study of 28 million people in France","volume":"19","author":"Semenzato","year":"2022","journal-title":"Lancet Reg Health Eur ao\u00fbt"},{"issue":"10","key":"10.1016\/j.jiph.2024.05.007_bib15","doi-asserted-by":"crossref","first-page":"ofad460","DOI":"10.1093\/ofid\/ofad460","article-title":"Protection of COVID-19 vaccination against hospitalization during the era of omicron BA.4 and BA.5 predominance: a nationwide case\u2013control study based on the French national health data system","volume":"10","author":"Semenzato","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiph.2024.05.007_bib16","unstructured":"Arr\u00eat\u00e9 du 21 avril 2020 compl\u00e9tant l\u2032arr\u00eat\u00e9 du 23 mars 2020 prescrivant les mesures d\u2032organisation et de fonctionnement du syst\u00e8me de sant\u00e9 n\u00e9cessaires pour faire face \u00e0 l\u2032\u00e9pid\u00e9mie de covid-19 dans le cadre de l\u2032\u00e9tat d\u2032urgence sanitaire\u2013L\u00e9gifrance [Internet]. [cit\u00e9 20 avr 2023]. Disponible sur: \u3008https:\/\/www.legifrance.gouv.fr\/loda\/id\/JORFTEXT000041812657\u3009."},{"key":"10.1016\/j.jiph.2024.05.007_bib17","unstructured":"Avis n\u00b0 2021.0069\/AC\/SESPEV du 23 septembre 2021 du coll\u00e8ge de la Haute Autorit\u00e9 de sant\u00e9 venant compl\u00e9ter l\u2032avis du 23 ao\u00fbt 2021 relatif \u00e0 la d\u00e9finition des populations \u00e0 cibler par la campagne de rappel vaccinal chez les personnes ayant eu une primovaccination compl\u00e8te contre la Covid-19 [Internet]. Haute Autorit\u00e9 de Sant\u00e9. [cit\u00e9 17 janv 2023]. Disponible sur: \u3008https:\/\/www.has-sante.fr\/jcms\/p_3288556\/fr\/avis-n-2021\u20130069\/ac\/sespev-du-23-septembre-2021-du-college-de-la-haute-autorite-de-sante-venant-completer-l-avis-du-23-aout-2021-relatif-a-la-definition-des-populations-a-cibler-par-la-campagne-de-rappel-vaccinal-chez-les-personnes-ayant-eu-une-primovaccination-complete-contre-la-covid-19\u3009."},{"key":"10.1016\/j.jiph.2024.05.007_bib18","unstructured":"Avis n\u00b0 2022.0005\/AC\/SESPEV modifiant l\u2032avis du 23 d\u00e9cembre 2021 du coll\u00e8ge de la Haute Autorit\u00e9 de sant\u00e9 relatif \u00e0 la diminution du d\u00e9lai entre primovaccination et administration d\u2032une dose de rappel chez les adolescents fragiles \u00e2g\u00e9s de 12 \u00e0 17 ans [Internet]. Haute Autorit\u00e9 de Sant\u00e9. [cit\u00e9 17 janv 2023]. Disponible sur: \u3008https:\/\/www.has-sante.fr\/jcms\/p_3309657\/fr\/avis-n-2022\u20130005\/ac\/sespev-modifiant-l-avis-du-23-decembre-2021-du-college-de-la-haute-autorite-de-sante-relatif-a-la-diminution-du-delai-entre-primovaccination-et-administration-d-une-dose-de-rappel-chez-les-adolescents-fragiles-ages-de-12-a-17-ans\u3009."},{"key":"10.1016\/j.jiph.2024.05.007_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2458-9-33","article-title":"Ecological association between a deprivation index and mortality in France over the period 1997\u20132001: variations with spatial scale, degree of urbanicity, age, gender and cause of death","volume":"9","author":"Rey","year":"2009","journal-title":"BMC Public Health"},{"issue":"9","key":"10.1016\/j.jiph.2024.05.007_bib20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/MLR.0000000000001745","article-title":"The economic burden of disease in france from the national health insurance perspective: the healthcare expenditures and conditions mapping used to prepare the French Social Security Funding Act and the Public Health Act","volume":"60","author":"Rachas","year":"2022","journal-title":"Med Care"},{"key":"10.1016\/j.jiph.2024.05.007_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)02465-5","article-title":"Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis","author":"Stein","year":"2023","journal-title":"Lancet f\u00e9vr"},{"key":"10.1016\/j.jiph.2024.05.007_bib22","unstructured":"Coronavirus: chiffres cl\u00e9s et \u00e9volution de la COVID-19 en France et dans le Monde [Internet]. [cit\u00e9 8 nov 2022]. Disponible sur: \u3008https:\/\/www.santepubliquefrance.fr\/dossiers\/coronavirus-covid-19\/coronavirus-chiffres-cles-et-evolution-de-la-covid-19-en-france-et-dans-le-monde\u3009."},{"key":"10.1016\/j.jiph.2024.05.007_bib23","unstructured":"D\u00e9cret n\u00b0 2016\u20131871 du 26 d\u00e9cembre 2016 relatif au traitement de donn\u00e9es \u00e0 caract\u00e8re personnel d\u00e9nomm\u00e9 \"\u00a0syst\u00e8me national des donn\u00e9es de sant\u00e9\u00a0\". 2016\u20131871 d\u00e9c 26, 2016."},{"key":"10.1016\/j.jiph.2024.05.007_bib24","unstructured":"Article R1461\u201313\u2013Code de la sant\u00e9 publique\u2013L\u00e9gifrance [Internet]. [cit\u00e9 21 avr 2023]. Disponible sur: \u3008https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000043723353\u3009."},{"key":"10.1016\/j.jiph.2024.05.007_bib25","unstructured":"Article R1461\u201314\u2013Code de la sant\u00e9 publique\u2013L\u00e9gifrance [Internet]. [cit\u00e9 21 avr 2023]. Disponible sur: \u3008https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000043723346\u3009."},{"key":"10.1016\/j.jiph.2024.05.007_bib26","unstructured":"Population par sexe et groupe d\u2032\u00e2ges | Insee [Internet]. [cit\u00e9 21 avr 2023]. Disponible sur: \u3008https:\/\/www.insee.fr\/fr\/statistiques\/2381474\u3009."},{"key":"10.1016\/j.jiph.2024.05.007_bib27","unstructured":"Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study\u2013The Lancet Regional Health\u2013Americas [Internet]. [cit\u00e9 24 mars 2023]. Disponible sur: \u3008https:\/\/www.thelancet.com\/journals\/lanam\/article\/PIIS2667\u2013193X(22)00114\u20134\/fulltext\u3009."},{"issue":"9","key":"10.1016\/j.jiph.2024.05.007_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.33446","article-title":"National core studies\u2014immunology breakthrough consortium. Evaluation of risk factors for postbooster Omicron COVID-19 Deaths in England","volume":"5","author":"Nafilyan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jiph.2024.05.007_bib29","article-title":"Risk of severe COVID-19 outcomes after autumn 2022 COVID-19 booster vaccinations: a pooled analysis of national prospective cohort studies involving 7.4 million adults in England, Northern Ireland, Scotland and Wales","volume":"37","author":"Bedston","year":"2024","journal-title":"Lancet Reg Health\u2013Eur [Internet]"},{"key":"10.1016\/j.jiph.2024.05.007_bib30","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41467-023-44276-x","article-title":"Risk ofCOVID-19 death in adults who received booster COVID-19 vaccinations in England","volume":"15","author":"Ward","year":"2024","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.jiph.2024.05.007_bib31","doi-asserted-by":"crossref","first-page":"e966","DOI":"10.1016\/S2468-2667(22)00223-7","article-title":"COVID-19 mortality and deprivation: pandemic, syndemic, and endemic health inequalities","volume":"7","author":"McGowan","year":"2022","journal-title":"Lancet Public Health"},{"issue":"10","key":"10.1016\/j.jiph.2024.05.007_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.34319","article-title":"Association of Household Deprivation, Comorbidities, and COVID-19 Hospitalisation in Children in Germany, January 2020 to July 2021","volume":"5","author":"Dragano","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.jiph.2024.05.007_bib33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13722-022-00349-8","article-title":"Risk of COVID-19 infection and the associated hospitalisation, ICU admission and mortality in opioid use disorder: a systematic review and meta-analysis","volume":"17","author":"Behnoush","year":"2022","journal-title":"Addict Sci Clin Pract"},{"key":"10.1016\/j.jiph.2024.05.007_bib34","article-title":"Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study","author":"Evans","year":"2023","journal-title":"Lancet Reg Health\u2013Eur"},{"issue":"7","key":"10.1016\/j.jiph.2024.05.007_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-012328","article-title":"Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis","volume":"8","author":"Relan","year":"2023","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.jiph.2024.05.007_bib36","first-page":"25","article-title":"Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study in Bristol, United Kingdom","author":"Hyams","year":"2023","journal-title":"Lancet Reg Health\u2013Eur [Internet]"},{"key":"10.1016\/j.jiph.2024.05.007_bib37","article-title":"Chronic diseases, health conditions and risk of COVID-19-related hospitalisation and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people","volume":"8","author":"Semenzato","year":"2021","journal-title":"Lancet Reg Health\u2013Eur"},{"key":"10.1016\/j.jiph.2024.05.007_bib38","first-page":"132","article-title":"Tobacco use among adults in 2020: results from the Sante publique France Health Barometer","author":"Pasquereau","year":"2021","journal-title":"Bull Epidemiol Hebd"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034124001473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034124001473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T04:28:28Z","timestamp":1718684908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034124001473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1876034124001473"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2024.05.007","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for COVID-19 hospitalisation after booster vaccination during the Omicron period: A French nationwide cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2024.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"102450"}}